The race to grab market share in the migraine space is becoming one of the most keenly-watched in pharma – and Aimovig (erenumab) is forecast to be the top-selling drug by 2026.
Novartis (NOVN: VX) and US biotech major Amgen (Nasdaq: AMGN), which are co-commercializing Aimovig in the USA, will feel even more confident in its prospects after The Lancet published full data from the LIBERTY study.
This trial was the first study of a calcitonin gene-related peptide (CGRP) receptor antagonist in a patient population where multiple treatments had previously failed.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze